PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.78%
R&D reduction while CRVO shows 38.27% growth. Joel Greenblatt would examine competitive risk.
-4.70%
G&A reduction while CRVO shows 4.76% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.44%
Operating expenses reduction while CRVO shows 34.18% growth. Joel Greenblatt would examine advantage.
-35.51%
Total costs reduction while CRVO shows 34.18% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
0.99%
D&A change of 0.99% while CRVO maintains D&A. Bruce Berkowitz would investigate efficiency.
41.12%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
40.44%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-17.42%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
42.50%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.50%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
40.54%
EPS change of 40.54% while CRVO is flat. Bruce Berkowitz would examine quality.
40.54%
Diluted EPS change of 40.54% while CRVO is flat. Bruce Berkowitz would examine quality.
0.40%
Share count change of 0.40% while CRVO is stable. Bruce Berkowitz would verify approach.
0.40%
Diluted share change of 0.40% while CRVO is stable. Bruce Berkowitz would verify approach.